Skip to main content
Top
Published in: Esophagus 2/2014

01-04-2014 | Original Article

Clinical significance of muscle layer interruption in T3 esophageal cancer

Authors: Keijiro Sugimura, Hiroshi Miyata, Makoto Yamasaki, Tsuyoshi Takahashi, Yukinori Kurokawa, Masaaki Motoori, Kiyokazu Nakajima, Shuji Takiguchi, Eiichi Morii, Masahiko Yano, Masaki Mori, Yuichiro Doki

Published in: Esophagus | Issue 2/2014

Login to get access

Abstract

Background

Patients with adventitia-invading (T3) tumors, which account for the majority of esophageal cancers, are indicated for surgery but still have a poor prognosis. Subclassifying T3 tumors based on clinical outcome would be useful for selecting adequate adjuvant therapies.

Methods

Using 268 esophageal cancer specimens from patients without preoperative treatment, the length of the vertical and longitudinal tumor invasion, entire esophageal wall thickness, and interruption of the outer muscle layer were measured. These morphological parameters correlated with clinico-pathological factors and outcome.

Results

Patients were classified as T1 (38.4 %), T2 (11.9 %), T3 (38.4 %), and T4 (11.2 %) and T stage correlated well with the four morphological parameters (p < 0.0001). Each of the four morphological parameters was a significant prognostic factor. A cutoff at 20 mm of muscle layer interruption (MLI) yielded the highest prognostic significance (5-year survival 36.7 vs. 59.1 %, p = 0.009). T3 tumors with <20 mm MLI showed survival rates equivalent to T2 tumors (5-year survival 59.5 %), whereas those with ≥20 mm MLI had survival rates similar to T4 tumors (5-year survival 26.7 %). Although lymphatic and hematogenic recurrence was not significantly different, local recurrences occurred more frequently in patients with T3 tumors with ≥20 mm MLI than in those with <20 mm MLI (4.3 vs. 21.4 %, p = 0.019).

Conclusions

T3 esophageal cancer can be classified into subgroups according to the length of MLI. Additional local treatment would be indicated for T3 tumors with >20 mm MLI.
Literature
1.
2.
go back to reference Eslick GD. Epidemiology of esophageal cancer. Gastroenterol Clin North Am. 2009;38(1):17–25 (pp vii).PubMedCrossRef Eslick GD. Epidemiology of esophageal cancer. Gastroenterol Clin North Am. 2009;38(1):17–25 (pp vii).PubMedCrossRef
3.
go back to reference Kollarova H, Machova L, Horakova D, Janoutova G, Janout V. Epidemiology of esophageal cancer–an overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151(1):17–20.PubMedCrossRef Kollarova H, Machova L, Horakova D, Janoutova G, Janout V. Epidemiology of esophageal cancer–an overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151(1):17–20.PubMedCrossRef
5.
go back to reference Kuraoka K, Hoshino E, Tsuchida T, Fujisaki J, Takahashi H, Fujita R. Early esophageal cancer can be detected by screening endoscopy assisted with narrow-band imaging (NBI). Hepatogastroenterology. 2009;56(89):63–6.PubMed Kuraoka K, Hoshino E, Tsuchida T, Fujisaki J, Takahashi H, Fujita R. Early esophageal cancer can be detected by screening endoscopy assisted with narrow-band imaging (NBI). Hepatogastroenterology. 2009;56(89):63–6.PubMed
6.
go back to reference Jacobson BC, Hirota W, Baron TH, Leighton JA, Faigel DO. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc. 2003;57(7):817–22.PubMedCrossRef Jacobson BC, Hirota W, Baron TH, Leighton JA, Faigel DO. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc. 2003;57(7):817–22.PubMedCrossRef
7.
go back to reference Soji Ozawa YT, Hideo B, Mitsuhiro F, Hisao M. Comprehensive registry of esophageal cancer in Japan, 2003. Esophagus. 2011;8:9–29.CrossRef Soji Ozawa YT, Hideo B, Mitsuhiro F, Hisao M. Comprehensive registry of esophageal cancer in Japan, 2003. Esophagus. 2011;8:9–29.CrossRef
8.
go back to reference Sobin LH, Hermanek P, Hutter RV. TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer. 1988;61(11):2310–4.PubMedCrossRef Sobin LH, Hermanek P, Hutter RV. TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer. 1988;61(11):2310–4.PubMedCrossRef
9.
go back to reference Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116(22):5336–9.PubMedCrossRef Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116(22):5336–9.PubMedCrossRef
10.
go back to reference Endo M, Yoshino K, Kawano T, Nagai K, Inoue H. Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus. 2000;13(2):125–9.PubMedCrossRef Endo M, Yoshino K, Kawano T, Nagai K, Inoue H. Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus. 2000;13(2):125–9.PubMedCrossRef
11.
go back to reference Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI. Dating the rise of esophageal adenocarcinoma: analysis of connecticut tumor registry data, 1940–2007. Cancer Epidemiol Biomarkers Prev. 2011;20(1):183–6.PubMedCentralPubMedCrossRef Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI. Dating the rise of esophageal adenocarcinoma: analysis of connecticut tumor registry data, 1940–2007. Cancer Epidemiol Biomarkers Prev. 2011;20(1):183–6.PubMedCentralPubMedCrossRef
12.
13.
go back to reference Wang BY, Goan YG, Hsu PK, Hsu WH, Wu YC. Tumor length as a prognostic factor in esophageal squamous cell carcinoma. Ann Thorac Surg. 2011;91(3):887–93.PubMedCrossRef Wang BY, Goan YG, Hsu PK, Hsu WH, Wu YC. Tumor length as a prognostic factor in esophageal squamous cell carcinoma. Ann Thorac Surg. 2011;91(3):887–93.PubMedCrossRef
14.
go back to reference Griffiths EA, Brummell Z, Gorthi G, Pritchard SA, Welch IM. Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses. J Surg Oncol. 2006;93(4):258–67.PubMedCrossRef Griffiths EA, Brummell Z, Gorthi G, Pritchard SA, Welch IM. Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses. J Surg Oncol. 2006;93(4):258–67.PubMedCrossRef
15.
go back to reference Miyata H, Yoshioka A, Yamasaki M, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer. 2009;115(14):3324–34.PubMedCrossRef Miyata H, Yoshioka A, Yamasaki M, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer. 2009;115(14):3324–34.PubMedCrossRef
16.
go back to reference Higashiyama M, Doi O, Kodama K, et al. Pleural lavage cytology immediately after thoracotomy and before closure of the thoracic cavity for lung cancer without pleural effusion and dissemination: clinicopathologic and prognostic analysis. Ann Surg Oncol. 1997;4(5):409–15.PubMedCrossRef Higashiyama M, Doi O, Kodama K, et al. Pleural lavage cytology immediately after thoracotomy and before closure of the thoracic cavity for lung cancer without pleural effusion and dissemination: clinicopathologic and prognostic analysis. Ann Surg Oncol. 1997;4(5):409–15.PubMedCrossRef
17.
go back to reference Jiao X, Zhang M, Wen Z, Krasna MJ. Pleural lavage cytology in esophageal cancer without pleural effusions: clinicopathologic analysis. Eur J Cardiothorac Surg. 2000;17(5):575–9.PubMedCrossRef Jiao X, Zhang M, Wen Z, Krasna MJ. Pleural lavage cytology in esophageal cancer without pleural effusions: clinicopathologic analysis. Eur J Cardiothorac Surg. 2000;17(5):575–9.PubMedCrossRef
18.
go back to reference Kondo H, Asamura H, Suemasu K, et al. Prognostic significance of pleural lavage cytology immediately after thoracotomy in patients with lung cancer. J Thorac Cardiovasc Surg. 1993;106(6):1092–7.PubMed Kondo H, Asamura H, Suemasu K, et al. Prognostic significance of pleural lavage cytology immediately after thoracotomy in patients with lung cancer. J Thorac Cardiovasc Surg. 1993;106(6):1092–7.PubMed
19.
go back to reference Doki Y, Kabuto T, Ishikawa O, et al. Does pleural lavage cytology before thoracic closure predict both patient’s prognosis and site of cancer recurrence after resection of esophageal cancer? Surgery. 2001;130(5):792–7.PubMedCrossRef Doki Y, Kabuto T, Ishikawa O, et al. Does pleural lavage cytology before thoracic closure predict both patient’s prognosis and site of cancer recurrence after resection of esophageal cancer? Surgery. 2001;130(5):792–7.PubMedCrossRef
20.
go back to reference Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2011;19(1):68–74.PubMedCrossRef Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2011;19(1):68–74.PubMedCrossRef
21.
go back to reference Pennathur A, Luketich JD, Landreneau RJ, et al. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg. 2008;85(6):1930–6 (discussion 6–7).PubMedCrossRef Pennathur A, Luketich JD, Landreneau RJ, et al. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg. 2008;85(6):1930–6 (discussion 6–7).PubMedCrossRef
22.
go back to reference Eisterer W, Dev A, Kendler D, et al. Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study. Anticancer Res. 2011;31(12):4407–12.PubMed Eisterer W, Dev A, Kendler D, et al. Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study. Anticancer Res. 2011;31(12):4407–12.PubMed
23.
go back to reference Osaka Y, Shinohara M, Hoshino S, et al. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res. 2011;31(2):633–8.PubMed Osaka Y, Shinohara M, Hoshino S, et al. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res. 2011;31(2):633–8.PubMed
24.
go back to reference Yokota T, Hatooka S, Ura T, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31(10):3535–41.PubMed Yokota T, Hatooka S, Ura T, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31(10):3535–41.PubMed
25.
go back to reference Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K, Takahashi T. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2010;66(6):1159–65.PubMedCentralPubMedCrossRef Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K, Takahashi T. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2010;66(6):1159–65.PubMedCentralPubMedCrossRef
26.
go back to reference Miyata H, Yamasaki M, Kurokawa Y, et al. Multimodal treatment for resectable esophageal cancer. Gen Thorac Cardiovasc Surg. 2011;59(7):461–6.PubMedCrossRef Miyata H, Yamasaki M, Kurokawa Y, et al. Multimodal treatment for resectable esophageal cancer. Gen Thorac Cardiovasc Surg. 2011;59(7):461–6.PubMedCrossRef
27.
go back to reference Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.PubMedCrossRef Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.PubMedCrossRef
28.
go back to reference Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19(2):305–13.PubMed Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19(2):305–13.PubMed
29.
go back to reference Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659–68.PubMedCrossRef Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659–68.PubMedCrossRef
30.
go back to reference Berger B, Stahlberg K, Lemminger A, Bleif M, Belka C, Bamberg M. Impact of radiotherapy, chemotherapy and surgery in multimodal treatment of locally advanced esophageal cancer. Oncology. 2011;81(5–6):387–94.PubMedCrossRef Berger B, Stahlberg K, Lemminger A, Bleif M, Belka C, Bamberg M. Impact of radiotherapy, chemotherapy and surgery in multimodal treatment of locally advanced esophageal cancer. Oncology. 2011;81(5–6):387–94.PubMedCrossRef
31.
go back to reference Yamasaki M, Miyata H, Tanaka K, et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80(5–6):307–13.PubMedCrossRef Yamasaki M, Miyata H, Tanaka K, et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80(5–6):307–13.PubMedCrossRef
32.
go back to reference Smith BR, Chang KJ, Lee JG, Nguyen NT. Staging accuracy of endoscopic ultrasound based on pathologic analysis after minimally invasive esophagectomy. Am Surg. 2010;76(11):1228–31.PubMed Smith BR, Chang KJ, Lee JG, Nguyen NT. Staging accuracy of endoscopic ultrasound based on pathologic analysis after minimally invasive esophagectomy. Am Surg. 2010;76(11):1228–31.PubMed
33.
go back to reference Twine CP, Roberts SA, Lewis WG, et al. Prognostic significance of endoluminal ultrasound-defined disease length and tumor volume (EDTV) for patients with the diagnosis of esophageal cancer. Surg Endosc. 2010;24(4):870–8.PubMedCrossRef Twine CP, Roberts SA, Lewis WG, et al. Prognostic significance of endoluminal ultrasound-defined disease length and tumor volume (EDTV) for patients with the diagnosis of esophageal cancer. Surg Endosc. 2010;24(4):870–8.PubMedCrossRef
34.
go back to reference Chang EY, Li X, Jerosch-Herold M, et al. The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. J Gastrointest Surg. 2008;12(1):166–75.PubMedCrossRef Chang EY, Li X, Jerosch-Herold M, et al. The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. J Gastrointest Surg. 2008;12(1):166–75.PubMedCrossRef
35.
go back to reference Sakurada A, Takahara T, Kwee TC, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol. 2009;19(6):1461–9.PubMedCrossRef Sakurada A, Takahara T, Kwee TC, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol. 2009;19(6):1461–9.PubMedCrossRef
36.
go back to reference Roedl JB, Harisinghani MG, Colen RR, et al. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. Ann Thorac Surg. 2008;86(4):1131–8.PubMedCrossRef Roedl JB, Harisinghani MG, Colen RR, et al. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. Ann Thorac Surg. 2008;86(4):1131–8.PubMedCrossRef
37.
go back to reference Zhong X, Yu J, Zhang B, et al. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;73(1):136–41.PubMedCrossRef Zhong X, Yu J, Zhang B, et al. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;73(1):136–41.PubMedCrossRef
Metadata
Title
Clinical significance of muscle layer interruption in T3 esophageal cancer
Authors
Keijiro Sugimura
Hiroshi Miyata
Makoto Yamasaki
Tsuyoshi Takahashi
Yukinori Kurokawa
Masaaki Motoori
Kiyokazu Nakajima
Shuji Takiguchi
Eiichi Morii
Masahiko Yano
Masaki Mori
Yuichiro Doki
Publication date
01-04-2014
Publisher
Springer Japan
Published in
Esophagus / Issue 2/2014
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-014-0420-1

Other articles of this Issue 2/2014

Esophagus 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine